Table 1.
Baseline characteristics
| Demographic data | Total (N = 40) |
|---|---|
| Age (yr) | 61.4 ± 14.2 |
| Male sex | 26 (65.0) |
| Body mass index (kg/m2) | 22.9 ± 3.8 |
| Concomitant disease | |
| Hypertension | 37 (92.5) |
| Diabetes mellitus | 14 (35.0) |
| Gout | 5 (12.5) |
| Dyslipidemia | 4 (10.0) |
| Systemic lupus erythematosus | 2 (5.0) |
| Thyrotoxicosis | 1 (2.5) |
| Cause ESRD | |
| Hypertensive nephropathy | 16 (40.0) |
| Diabetic kidney disease | 12 (30.0) |
| Others | 11 (27.5) |
| Unknown | 1 (2.5) |
| Predialysis blood pressure (mm Hg) | |
| Systolic blood pressure | 146.6 ± 11.2 |
| Diastolic blood pressure | 69.0 ± 10.4 |
| Mean arterial pressure | 94.9 ± 9.3 |
| Vascular access | |
| Arteriovenous fistula/graft | 35 (87.5) |
| Tunneled-cuff catheter | 4 (10.0) |
| Temporary catheter | 1 (2.5) |
| Dialysis session (times/wk) | |
| 2 times/wk | 23 (57.5) |
| 3 times/wk | 16 (40.0) |
| 4 times/wk | 1 (2.5) |
| Dialysis vintage (mo), median [IQR] | 28.5 [13.0–44.5] |
| Dry weight (kg) | 57.8 ± 11.7 |
| Total fluid removal (l/treatment) | 2.4 ± 1.2 |
| Length of dialysis treatment (h) | 3.98 ± 0.16 |
| Ultrafiltration rate (ml/h/kg) | 10.7 ± 5.1 |
| Recent Kt/V | 1.68 ± 0.38 |
| Number of antihypertensive drugs | 2.8 ± 1.9 |
| Antihypertensive drug | |
| Calcium channel blocker | 30 (75.0) |
| Beta-blocker | 27 (67.5) |
| Alpha-blocker | 12 (30.0) |
| Hydralazine | 10 (25.0) |
| ACEI/ARB | 9 (22.5) |
| Diuretics | 9 (22.5) |
| Methyldopa | 6 (15.0) |
| Isosorbide dinitrate | 6 (15.0) |
| Spironolactone | 4 (10.0) |
| Laboratory data | |
| Hemoglobin (g/d) | 10.3 ± 1.6 |
| Transferrin saturation (%) | 28.8 ± 13.7 |
| Ferritin (μg/l), median [IQR] | 368 [243–613] |
| Blood urea nitrogen (mmol/l) | 20.8 ± 5.9 |
| Serum creatinine (μmol/l) | 805 ± 268 |
| Serum sodium (mmol/l) | 137 ± 3 |
| Serum potassium (mmol/l) | 4.4 ± 0.7 |
| Serum chloride (mmol/l) | 98 ± 4 |
| Serum bicarbonate (mmol/l) | 23.3 ± 4.2 |
| Serum calcium (mmol/l) | 2.2 ± 0.2 |
| Serum phosphate (mmol/l) | 1.5 ± 0.5 |
| Serum albumin (g/l) | 41 ± 5 |
| Intact parathyroid hormone (ng/l), median [IQR] | 169 [109–317] |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ESRD, end-stage renal disease; IQR, interquartile range.
Data were presented in mean ± SD or n (%), otherwise specified.